Compare OCFC & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCFC | BBOT |
|---|---|---|
| Founded | 1902 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | OCFC | BBOT |
|---|---|---|
| Price | $18.56 | $10.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $21.33 | ★ $23.71 |
| AVG Volume (30 Days) | ★ 571.7K | 286.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $46.71 | N/A |
| Revenue Next Year | $21.25 | N/A |
| P/E Ratio | $16.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.29 | $8.70 |
| 52 Week High | $20.61 | $14.87 |
| Indicator | OCFC | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 40.00 |
| Support Level | $17.24 | $9.69 |
| Resistance Level | $19.11 | $12.65 |
| Average True Range (ATR) | 0.61 | 0.76 |
| MACD | -0.13 | -0.05 |
| Stochastic Oscillator | 40.68 | 20.66 |
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.